We bring high-value technologies designed to solve critical, analytical problems. We enable profound discoveries, optimize lab operations and ensure regulatory compliance. We help customers turn global industry challenges into the medicines that offer hope.
Audit readiness isn’t a last-minute activity triggered by validation or inspection. It’s established much earlier, at method design, through the scientific understanding, risk-based control, and documentation needed to demonstrate that a method is fit for purpose and capable of performing consistently over time. If those elements aren’t built in from the outset, gaps are likely…
Ensuring the stability of recombinant adeno-associated virus (rAAV) vectors remains a central challenge in gene therapy development. rAAV particles are structurally complex, highly heterogeneous, and sensitive to environmental stress, making it difficult to link analytical changes to functional consequences during manufacturing and storage. A recent Journal of Pharmaceutical Sciencesstudy by Prof. Susumu Uchiyama and colleaguesat…
Understanding how bacterial proteasomes recognize and process their substrates remains a major challenge in infectious disease biology and drug discovery. In Mycobacterium tuberculosis, this challenge is particularly critical, as the proteasome is essential for bacterial survival inside host macrophages and represents an attractive antibacterial target. A recent Nature Communications study by Prof. Siavash Vahidi and…
Adeno-associated virus (AAV) vectors are widely used in gene therapy because of their ability to enable long-term transgene expression with favorable safety profiles. However, immune responses to the AAV capsid remain a major barrier, limiting treatment durability and the feasibility of repeat dosing. A recent Nature Communications study led by Dr. Ronit Mazor and colleagues…
In drug manufacturing, there is no room for error. Every decision, from early formulation to final release, must ensure a product is safe, effective, and consistent. At the center of this process are critical quality attributes (CQAs), the measurable properties that define whether a drug meets its required standards. In this blog, we break down…
In hospital intensive care units, insulin is a critical therapeutic used to maintain tight glycemic control. While it is typically supplied at 100 units/mL, clinical protocols dilute it to 1 unit/mL for continuous infusion, commonly known as the insulin infusion protocol (IIP). At these low concentrations, ensuring stability becomes challenging, especially when aggregation or surface…
Biologics developers today face unprecedented pressure: tighter timelines, increasingly complex antibody formats, and a growing need for real-time process understanding. Yet many analytical workflows still rely on methods that can’t deliver the speed, sensitivity, or depth required for modern bioprocessing. That’s where advances in Protein A (ProA) affinity chromatography are making a meaningful difference, reshaping…
The Role of Enzymes in LC-MS Analysis of Modern Biotherapeutics Enzymes are nature’s catalysts, enabling precise and efficient biochemical transformations. In analytical workflows, enzymatic digestion is a cornerstone technique for breaking down complex biomolecules into smaller, more manageable fragments. This process is critical for applications such as peptide mapping in protein characterization and oligonucleotide mapping…
The FDA’s October 29, 2025 draft guidance has generated significant attention due to the implications for both developers and patients. By allowing developers to bypass comparative efficacy studies (CES) when advanced analytics are successful substitutes, the draft guidance avoids one of the most expensive steps, estimated to account for 70% of the total biosimilar development…
How Sygnature Discovery Supports the 3Rs with LC-MS/MS Scientific Precision and Ethical Innovation In the world of drug discovery, researchers face a critical challenge: how do you generate high-quality, reproducible bioanalytical data while minimizing the ethical and logistical burden of using animals in testing? This is especially so with central nervous system (CNS) drug discovery,…
Whether you are analyzing adeno-associated viruses (AAVs) or virus-like particles, nucleic acids such as RNAs or lipid nanoparticles (LNPs), proteins, or protein complexes, simple and fit-for-purpose tools with speed, accuracy, and precision are essential for driving biotherapeutic innovations forward. In recent years, scientists have increasingly turned to charge detection mass spectrometry (CDMS).
In the realm of cutting-edge medical treatments, cell therapy products have emerged as revolutionary tools in combating a myriad of diseases, ranging from cancer to genetic disorders. These therapies harness the power of living cells to regenerate damaged tissue, modulate immune responses, or directly target malignant cells. However, amidst the promise of these novel treatments…